Jerry Kelly and Exact Sciences Team Up to Promote Colon Cancer Screening

Golfer launches multi-year, Cologuard®-branded campaign

MADISON, Wis., June 22, 2017 /PRNewswire/ -- Exact Sciences today announced it is teaming up with Madison professional golfer Jerry Kelly to help drive home the importance of colorectal cancer screening.  Beginning at this week's American Family Insurance Championship, Kelly will wear a Cologuard-branded hat for the next two years at tournaments around the country to help raise awareness of colon cancer and the importance of regular screening beginning at age 50 for individuals at average risk.

Read More

A Strong Start to 2017

Exact Sciences recently announced our first quarter 2017 financial results, highlighting the accelerating growth trajectory for Cologuard.  Beyond the headline-making news, we continue to see a large market opportunity for Cologuard. While changing the standard of care will take time and investment in our infrastructure, we have never been more confident in the long-term growth of Cologuard and Exact Sciences.  

Read More

Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests

  • Gross margin expands to 65 percent during first quarter
  • Revenue guidance raised to $195-205 million for 2017, from $170-180 million;
  • Guidance for completed Cologuard tests increased to at least 470,000 tests, from at least 415,000;
  • 10,000 additional providers ordered Cologuard during the first quarter, and insurance coverage expanded to 78 percent.

MADISON, Wis., April 27, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $48.4 million and completed approximately 100,000 Cologuard tests during the quarter ended March 31, 2017. First-quarter 2017 revenues and completed Cologuard test volume grew 226 percent and 150 percent from the same period of 2016, respectively.

Read More

Topics: Investor Relations

CMS includes Cologuard in updated Medicare Advantage Star Ratings



MADISON, Wis., April 4, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) included Cologuard® in its updated Medicare Advantage Star Ratings program. Medicare Advantage plans now can help increase their Star Ratings when their beneficiaries complete Cologuard, Exact Sciences' non-invasive colon cancer screening test. 
Read More

Exact Sciences and Mayo Clinic study shows promise of new blood-based lung cancer test

AACR abstract highlights methylation markers capable of detecting all types of lung cancer with more than 90% sensitivity and specificity

MADISON, Wis., March 1, 2017 /PRNewswire/ -- A study from Exact Sciences Corp. (Nasdaq: EXAS) and Mayo Clinic released today by the American Association of Cancer Research (AACR) shows promise for the development of a blood-based lung cancer test. Researchers conducted a multi-round study of nearly 400 patients, which demonstrated high accuracy for detecting lung cancer at all stages.

Read More

Highlighting our Mission in March

Exact Sciences’ first mission is to help eradicate colon cancer. That mission is on the minds of our team members every single day, and March gives us an opportunity to be even louder about the work we do. Right now, our team members are preparing to take part in some big events to help spread awareness about the nation’s second deadliest cancer and the need for screening.

Read More

Exact Sciences generated $99.4 million in revenues during 2016, a 152-percent increase


Cologuard gross margin reached 61 percent in fourth quarter

MADISON, Wis., Feb. 21, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $99.4 million and completed approximately 244,000 Cologuard tests during the year ended Dec. 31, 2016. Full-year 2016 revenues and Cologuard test volume grew 152 percent and 135 percent from 2015, respectively.

Read More

CMS Proposes Inclusion of Cologuard in Medicare Advantage Star Ratings


Cologuard offers health plans an opportunity to increase screening & improve quality ratings

MADISON, Wis., Feb. 2, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Cologuard® is included in the Medicare Advantage Advance Notice and Draft Call letter.  Cologuard's inclusion in the final Star Ratings will allow Medicare Advantage plans to increase their Star Rating when patients complete Exact Sciences' non-invasive colon cancer screening test.

Read More